Algorithm for Choice of Treatment for Cognitive Impairment in Current Clinical Practice
The paper summarizes main causes and pathogenetic mechanisms of the development of cognitive impairment in patients with the most common chronic non-infectious diseases. We consider opportunities in choosing therapeutic strategy for managing patients with cognitive disorders. We evaluate the efficacy of the drug agent Cereton in comparison with Actovegin in relation to the indicated patient population based on the data obtained from clinical trials. We conclude that use of Cereton as monotherapy for cognitive impairment treatment appears to be more reasonable and preferable than use of Actovegin.